Literature DB >> 33255420

FDG PET/CT Findings of Castleman Disease Assessed by Histologic Subtypes and Compared with Laboratory Findings.

Eun Ji Han1, Joo Hyun O2, Seung-Eun Jung3, Gyeongsin Park4, Byung-Ock Choi5, Young-Woo Jeon6, Gi-June Min7, Seok-Goo Cho7.   

Abstract

Castleman disease (CD) is a relatively rare lymphoproliferative disorder and the pathophysiology of the subtypes are incompletely understood. Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) demonstrates the metabolic activity of inflammatory and tumorous conditions. The FDG uptake intensity and sites of involved lesions on FDG PET/CT were assessed by histologic subtypes, and compared to the patient's hemoglobin, platelet, albumin, and high-sensitivity C-reactive protein (hs-CRP) levels. In total, 60 PET/CT images of 44 consecutive CD patients were included: 4 (9%) unicentric and 40 (91%) multicentric; 21 (48%) hyaline vascular subtype, 16 (36%) plasma cell, and 7 (16%) mixed or unclassified. The maximum standardized uptake value (SUVmax) and tumor-to-liver (T/L) ratio of involved lymph nodes (LNs) were 5.3 ± 2.4 (range, 1.6-11.5) and 2.8 ± 1.6 (range, 1.1-9.6), respectively, with no significant difference between the histologic subtypes. Higher number of involved LN stations and presence of extra-nodal involvement on FDG PET/CT were associated with thrombocytopenia, hypoalbuminemia, and elevated hs-CRP levels (p values < 0.05). FDG-avidity was not different by histologic subtypes and did not correlate with laboratory findings. However, the extent of nodal and extra-nodal involvement as noted on FDG PET/CT was significantly associated with abnormal laboratory findings in patients with CD.

Entities:  

Keywords:  FDG; PET/CT; castleman disease; hypoalbuminemia; thrombocytopenia

Year:  2020        PMID: 33255420      PMCID: PMC7761046          DOI: 10.3390/diagnostics10120998

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  33 in total

Review 1.  The spectrum of Castleman's disease: mimics, radiologic pathologic correlation and role of imaging in patient management.

Authors:  Rachna Madan; Jey-Hsin Chen; Beatrice Trotman-Dickenson; Francine Jacobson; Andetta Hunsaker
Journal:  Eur J Radiol       Date:  2010-07-18       Impact factor: 3.528

2.  Unicentric and multicentric Castleman's disease.

Authors:  K Enomoto; I Nakamichi; K Hamada; A Inoue; I Higuchi; M Sekimoto; M Mizuki; Y Hoshida; T Kubo; K Aozasa; J Hatazawa
Journal:  Br J Radiol       Date:  2007-01       Impact factor: 3.039

3.  FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease.

Authors:  Rob Barker; Fahrad Kazmi; Justin Stebbing; Sarah Ngan; Roger Chinn; Mark Nelson; Michael O'Doherty; Mark Bower
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-03       Impact factor: 9.236

4.  Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Authors:  Mark N Polizzotto; Thomas S Uldrick; Victoria Wang; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Stefania Pittaluga; Deirdre O'Mahony; Denise Whitby; Giovanna Tosato; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

Review 5.  Castleman's disease: systematic analysis of 416 patients from the literature.

Authors:  Nadia Talat; Klaus-Martin Schulte
Journal:  Oncologist       Date:  2011-07-17

Review 6.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

7.  18 FDG-PET/CT: 21st century approach to leukemic tumors in 124 cases.

Authors:  Isabel Cunningham; Brigett Kohno
Journal:  Am J Hematol       Date:  2016-02-09       Impact factor: 10.047

Review 8.  Castleman disease: the great mimic.

Authors:  David Bonekamp; Karen M Horton; Ralph H Hruban; Elliot K Fishman
Journal:  Radiographics       Date:  2011-10       Impact factor: 5.333

9.  FDG PET in lymphoma: the need for standardization of interpretation. An observer variation study.

Authors:  Josée M Zijlstra; Emile F Comans; Arthur van Lingen; Otto S Hoekstra; Chad M Gundy; Jan Willem Coebergh; Vivian Bongers
Journal:  Nucl Med Commun       Date:  2007-10       Impact factor: 1.690

Review 10.  HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

Authors:  David C Fajgenbaum; Frits van Rhee; Christopher S Nabel
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113

View more
  1 in total

1.  Treatment and Outcome of Castleman Disease: A Retrospective Report of 31 Patients.

Authors:  Dijiao Tang; Yuetong Guo; Yi Tang; Hongxu Wang
Journal:  Ther Clin Risk Manag       Date:  2022-04-26       Impact factor: 2.755

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.